vs
Side-by-side financial comparison of ENTEGRIS INC (ENTG) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
ENTEGRIS INC is the larger business by last-quarter revenue ($823.9M vs $708.5M, roughly 1.2× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 6.0%, a 13.1% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -3.1%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $134.0M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 3.4%).
Entegris, Inc. is a supplier of materials for the semiconductor and other high-tech industries. Entegris has approximately 8,000 employees throughout its global operations. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. The company’s corporate headquarters are in Billerica, Massachusetts.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ENTG vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $823.9M | $708.5M |
| Net Profit | $49.4M | $135.1M |
| Gross Margin | 43.8% | — |
| Operating Margin | 12.7% | 21.6% |
| Net Margin | 6.0% | 19.1% |
| Revenue YoY | -3.1% | 32.0% |
| Net Profit YoY | -51.7% | 15.5% |
| EPS (diluted) | $0.33 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $823.9M | $708.5M | ||
| Q3 25 | $807.1M | $659.9M | ||
| Q2 25 | $792.4M | $603.3M | ||
| Q1 25 | $773.2M | $558.6M | ||
| Q4 24 | $849.8M | $536.6M | ||
| Q3 24 | $807.7M | $533.3M | ||
| Q2 24 | $812.7M | $528.1M | ||
| Q1 24 | $771.0M | $511.0M |
| Q4 25 | $49.4M | $135.1M | ||
| Q3 25 | $70.5M | $111.1M | ||
| Q2 25 | $52.8M | $90.3M | ||
| Q1 25 | $62.9M | $114.6M | ||
| Q4 24 | $102.2M | $117.0M | ||
| Q3 24 | $77.6M | $96.4M | ||
| Q2 24 | $67.7M | $88.4M | ||
| Q1 24 | $45.3M | $102.6M |
| Q4 25 | 43.8% | — | ||
| Q3 25 | 43.5% | — | ||
| Q2 25 | 44.4% | — | ||
| Q1 25 | 46.1% | — | ||
| Q4 24 | 45.6% | — | ||
| Q3 24 | 46.0% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.6% | — |
| Q4 25 | 12.7% | 21.6% | ||
| Q3 25 | 15.2% | 21.5% | ||
| Q2 25 | 13.4% | 20.9% | ||
| Q1 25 | 15.8% | 20.3% | ||
| Q4 24 | 17.6% | 23.4% | ||
| Q3 24 | 16.9% | 21.1% | ||
| Q2 24 | 16.0% | 19.9% | ||
| Q1 24 | 15.3% | 20.4% |
| Q4 25 | 6.0% | 19.1% | ||
| Q3 25 | 8.7% | 16.8% | ||
| Q2 25 | 6.7% | 15.0% | ||
| Q1 25 | 8.1% | 20.5% | ||
| Q4 24 | 12.0% | 21.8% | ||
| Q3 24 | 9.6% | 18.1% | ||
| Q2 24 | 8.3% | 16.7% | ||
| Q1 24 | 5.9% | 20.1% |
| Q4 25 | $0.33 | $4.65 | ||
| Q3 25 | $0.46 | $3.86 | ||
| Q2 25 | $0.35 | $3.10 | ||
| Q1 25 | $0.41 | $3.67 | ||
| Q4 24 | $0.67 | $3.67 | ||
| Q3 24 | $0.51 | $3.01 | ||
| Q2 24 | $0.45 | $2.75 | ||
| Q1 24 | $0.30 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $360.4M | $497.0M |
| Total DebtLower is stronger | $3.7B | — |
| Stockholders' EquityBook value | $4.0B | $459.1M |
| Total Assets | $8.4B | $2.0B |
| Debt / EquityLower = less leverage | 0.94× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $360.4M | $497.0M | ||
| Q3 25 | $399.8M | $285.4M | ||
| Q2 25 | $376.8M | $46.3M | ||
| Q1 25 | $340.9M | $441.4M | ||
| Q4 24 | $329.2M | $669.4M | ||
| Q3 24 | $432.1M | $656.9M | ||
| Q2 24 | $320.0M | $510.9M | ||
| Q1 24 | $340.7M | $407.0M |
| Q4 25 | $3.7B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $4.0B | — | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.1B | — | ||
| Q1 24 | $4.2B | — |
| Q4 25 | $4.0B | $459.1M | ||
| Q3 25 | $3.9B | $293.6M | ||
| Q2 25 | $3.8B | $172.4M | ||
| Q1 25 | $3.7B | $593.6M | ||
| Q4 24 | $3.7B | $825.5M | ||
| Q3 24 | $3.6B | $881.4M | ||
| Q2 24 | $3.5B | $763.6M | ||
| Q1 24 | $3.4B | $671.5M |
| Q4 25 | $8.4B | $2.0B | ||
| Q3 25 | $8.4B | $1.8B | ||
| Q2 25 | $8.4B | $1.6B | ||
| Q1 25 | $8.4B | $1.9B | ||
| Q4 24 | $8.4B | $2.1B | ||
| Q3 24 | $8.5B | $2.1B | ||
| Q2 24 | $8.3B | $1.9B | ||
| Q1 24 | $8.4B | $1.8B |
| Q4 25 | 0.94× | — | ||
| Q3 25 | 0.99× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.08× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 1.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.0M | $192.7M |
| Free Cash FlowOCF − Capex | $134.0M | $188.1M |
| FCF MarginFCF / Revenue | 16.3% | 26.6% |
| Capex IntensityCapex / Revenue | 7.0% | 0.6% |
| Cash ConversionOCF / Net Profit | 3.89× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $396.2M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.0M | $192.7M | ||
| Q3 25 | $249.5M | $246.2M | ||
| Q2 25 | $113.5M | $148.5M | ||
| Q1 25 | $140.4M | $125.8M | ||
| Q4 24 | $176.1M | $190.7M | ||
| Q3 24 | $197.2M | $149.1M | ||
| Q2 24 | $111.2M | $116.4M | ||
| Q1 24 | $147.2M | $152.7M |
| Q4 25 | $134.0M | $188.1M | ||
| Q3 25 | $182.8M | $235.5M | ||
| Q2 25 | $47.0M | $142.4M | ||
| Q1 25 | $32.4M | $115.8M | ||
| Q4 24 | $68.6M | $183.0M | ||
| Q3 24 | $115.0M | $138.5M | ||
| Q2 24 | $51.9M | $103.5M | ||
| Q1 24 | $80.6M | $147.2M |
| Q4 25 | 16.3% | 26.6% | ||
| Q3 25 | 22.6% | 35.7% | ||
| Q2 25 | 5.9% | 23.6% | ||
| Q1 25 | 4.2% | 20.7% | ||
| Q4 24 | 8.1% | 34.1% | ||
| Q3 24 | 14.2% | 26.0% | ||
| Q2 24 | 6.4% | 19.6% | ||
| Q1 24 | 10.4% | 28.8% |
| Q4 25 | 7.0% | 0.6% | ||
| Q3 25 | 8.3% | 1.6% | ||
| Q2 25 | 8.4% | 1.0% | ||
| Q1 25 | 14.0% | 1.8% | ||
| Q4 24 | 12.7% | 1.4% | ||
| Q3 24 | 10.2% | 2.0% | ||
| Q2 24 | 7.3% | 2.4% | ||
| Q1 24 | 8.6% | 1.1% |
| Q4 25 | 3.89× | 1.43× | ||
| Q3 25 | 3.54× | 2.22× | ||
| Q2 25 | 2.15× | 1.65× | ||
| Q1 25 | 2.23× | 1.10× | ||
| Q4 24 | 1.72× | 1.63× | ||
| Q3 24 | 2.54× | 1.55× | ||
| Q2 24 | 1.64× | 1.32× | ||
| Q1 24 | 3.25× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
